Tumor-induced Osteomalacia: A Comprehensive Review.
Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A, Pepe J, Cipriani C, Thakker RV.
Endocr Rev. 2023 Mar 4;44(2):323-353. doi: 10.1210/endrev/bnac026.
PMID:36327295
Burosumab for the Treatment of Tumor-Induced Osteomalacia.
Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO.
J Bone Miner Res. 2021 Apr;36(4):627-635. doi: 10.1002/jbmr.4233. Epub 2021 Jan 12.
PMID:33338281
Tumor-induced osteomalacia.
Florenzano P, Gafni RI, Collins MT.
Bone Rep. 2017 Sep 20;7:90-97. doi: 10.1016/j.bonr.2017.09.002. eCollection 2017 Dec.
PMID:29021995
Tumor-induced osteomalacia treated with T12 tumor resection.
Mancini AJ, Sabet A, Nielsen GP, Parker JA, Schwab JH, Ward A, Wu JS, Malabanan AO.
Endocrinol Diabetes Metab Case Rep. 2022 Dec 1;2022:22-0344. doi: 10.1530/EDM-22-0344. Online ahead of print.
PMID:36511458
Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia.
Jan de Beur SM, Minisola S, Xia WB, Abrahamsen B, Body JJ, Brandi ML, Clifton-Bligh R, Collins M, Florenzano P, Houillier P, Imanishi Y, Imel EA, Khan AA, Zillikens MC, Fukumoto S.